MedTrace Logo

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women

NCT03228680 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 373

Last updated 2023-08-24

Study results available
· View outcomes & findings →

Summary

To demonstrate non-inferiority of FE 999049 compared to FOLLISTIM with respect to number of oocytes retrieved in Japanese IVF/ICSI patients undergoing controlled ovarian stimulation.

Conditions

Interventions

DRUG

Follitropin delta

Single daily subcutaneous administration through pre-filled injection pen

DRUG

Follitropin beta

Single daily subcutaneous injection in the abdomen

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-29
Primary Completion
2019-06-10
Completion
2019-07-08

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228680 on ClinicalTrials.gov